Representatives from companies such as Sanofi and Forge Biologics point to the potential for PreCheck to drive activation of ...

Kezar Life Sciences suffered multiple clinical holds and four patient deaths in a trial testing zetomipzomib for lupus—a ...

“No need for a reunion show: This seasons Real Housewives of Biopharma comes to a close with Pfizer’s winning bid for Metsera ...

The White Houes may have struck a deal with Eli Lilly and Novo Nordisk last week to lower the costs of their weight loss ...

MeiraGTx Holdings is licensing a genetic eye disease medicine to Eli Lilly in a deal worth up to $475 million.

After a leading study caused the FDA to slap its most stringent warning on hormone replacement therapies for menopause more ...

Multiple analyst firms were impressed by the Phase III data, which showed that Merck’s oral PCSK9 inhibitor can lower ...

Ionis is planning a supplemental submission by the end of the year to expand Tryngolza into severe hypertriglyceridemia. If ...

The cholesterol-lowering drug is part of a suite of medicines that also includes MariTide and that Amgen Chief Medical Officer Paul Burton hopes will make the company the “undisputed leader in the ...

A new generation of companies is eyeing the existing, sizeable hair loss market, hoping that better formulations and new ...

Pressure from the FTC and Pfizer is building around Novo Nordisk’s bid to snatch obesity biotech Metsera. The antitrust ...

The agreement will also secure a $150 price for future weight loss pills from Novo Nordisk and Eli Lilly—at least initially.